SCHEMBL12466797

SCHEMBL12466797

N=C(N)c1ccc(CNC(=O)N2CCC(Cc3ccccc3)CC2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.77
KMT2A Q03164 2/20 0.77
TPSAB1 Q15661 5/20 0.62
F2 P00734 5/20 0.59
PRSS1 P07477 2/20 0.59
PRSS2 P07478 1/20 0.59
PRSS3 P35030 1/20 0.59
TPSD1 Q9BZJ3 1/20 0.59
TPSG1 Q9NRR2 1/20 0.59
NPSR1 Q6W5P4 1/20 0.56
FAAH O00519 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
GRIN2B Q13224 1/20 0.54
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC10 Q969S8 1/20 0.54
HDAC11 Q96DB2 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12466291 0.89 MEN1 (0.60) MEN1KMT2ATPSAB1F2PRSS1
SCHEMBL12466583 0.88 MEN1 (0.85) MEN1KMT2ANPSR1FAAHSMN1; SMN2
SCHEMBL12466909 0.87 KMT2A (0.74) MEN1KMT2ATPSAB1NPSR1FAAH
SCHEMBL12685846 0.86 MEN1 (0.85) MEN1KMT2ATPSAB1TPSD1TPSG1
SCHEMBL12685780 0.86 MEN1 (0.85) MEN1KMT2ATPSAB1NPSR1FAAH
Hydrochloric Acid SCHEMBL12466326 0.85 MEN1 (0.83) MEN1KMT2ATPSAB1TPSD1TPSG1
SCHEMBL12466228 0.84 MEN1 (0.77) MEN1KMT2ANPSR1FAAHSMN1; SMN2
SCHEMBL12466655 0.84 MEN1 (0.77) MEN1KMT2ANPSR1FAAHSMN1; SMN2
Trifluoroacetic Acid SCHEMBL27943775 0.81 KMT2A (0.65) MEN1KMT2ANPSR1FAAHSMN1; SMN2
SCHEMBL12468347 0.81 MEN1 (0.71) MEN1KMT2ANPSR1FAAHSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130324556-A1 Protease Activated Receptor 2 (PAR2) Antagonists PROXIMAGEN LTD. (GB) 2013-12-05 US claimed
EP-2668157-A1 PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS Proximagen Limited (GB) 2013-12-04 EP claimed
WO-2012101453-A1 PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS PROXIMAGEN LTD. (GB) 2012-08-02 WO claimed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 WO disclosed
US-20130324556-A1 Protease Activated Receptor 2 (PAR2) Antagonists PROXIMAGEN LTD. (GB) 2013-12-05 US disclosed
EP-2668157-A1 PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS Proximagen Limited (GB) 2013-12-04 EP disclosed
WO-2012101453-A1 PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS PROXIMAGEN LTD. (GB) 2012-08-02 WO disclosed
WO-2012101453-A1 PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS PROXIMAGEN LTD. (GB) 2012-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130324556-A1 Protease Activated Receptor 2 (PAR2) Antagonists F2RL1, F2R, F2RL3 MEN1 1376/4885KMT2A 2337/4885TPSAB1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.